Welcome to the Epidemic Preparedness Innovations (EPI) web space. This platform has been set up by the Coalition for Epidemic Preparedness Innovations (CEPI). It is under development and aims to bring together knowledge, tools and methods to support vaccine researchers, developers, funders and anybody working on or interested in the field of epidemic preparedness innovations.

What are the objectives of this platform?

The aim of this platform is to establish a clinical knowledge hub for anybody working on or interested in the field of epidemic preparedness innovations. With a rapidly growing portfolio of vaccine candidates in development and preparations for clinical trials and studies in affected countries underway, the need for information and resources that can be readily shared in a central, online location with the opportunity for interactive communication from and to CEPI and amongst all stakeholders has become greater.

The objectives of the Epidemic Preparedness Innovations platform, in line with CEPI’s objectives, are to:

  • Provide expert assistance to developers and investigators to enhance vaccine development efforts
  • Engage stakeholders
  • Drive efficiencies in vaccine development to reduce costs and provide access to CEPI products
  • Ensure open access to data, results and publications arising from CEPI’s funding and facilitate access to materials to accelerate vaccine development
  • Develop partnerships for knowledge sharing and quality relations between partners in vaccine development in alignment with CEPI objectives
  • Provide capacity development in affected countries through clinical trial tools, training, workshops, and web-learning courses
  • Facilitate professional development and knowledge exchange between vaccine developers, investigational sites and funding agencies

Who may benefit from engaging in this platform?

You may benefit from this platform if you/your organization pertain to one of the following groups:

  • Vaccine research and development organizations and academic institutions working on clinical trials within the scope of CEPI-funded WHO R&D Blueprint priority pathogens (see details further below)
  • Enabling science organizations
  • Not-for profit implementation organizations
  • Clinical trial sites and investigators working in the disease areas and countries where CEPI and CEPI’s partners are working
  • Scientific and development communities in priority diseases
  • WHO representatives and ministries of health in affected countries where CEPI’s partners are working as well as other interested countries.

What is CEPI and what does CEPI do?

CEPI is an innovative global partnership between public, private, philanthropic, and civil society organizations working to accelerate the development of vaccines against emerging infectious diseases and to enable equitable access to these vaccines for affected populations during outbreaks. 

CEPI was launched at the World Economic Forum in Davos in 2017 as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics. 

CEPI’s headquarters are in Oslo, Norway, and there are offices in London, UK, and Washington DC, USA. CEPI also works closely with public-sector, private-sector, and civil-society partners around the world. 

CEPI and its partners work on the following priority diseases:





Themis Bioscience
IDT Biologika
Janssen Vaccines & University of Oxford
University of Queensland


 Lassa Fever


Profectus Biosciences, Emergent Biosolutions & PATH
Inovio Pharmaceuticals
International AIDS Vaccine Initiative (IAVI)
Themis Bioscience
Janssen Vaccines & University of Oxford



Public Health Vaccines
University of Oxford
Previously with: University of Tokyo

Rift Valley Fever

Colorado State University
Wageningen Bioveterinary Research


Valneva & Instituto Butantan
IVI & Bharat Biotech
Previously with: Themis Bioscience


Clover Biopharmaceuticals, Gritstone bio, VBI, SK bioscience, Moderna, Novavax, Vaxxinity, Medigen
Previously with: Biological E Ltd, CureVac, Shanghai Zerun Biotechnology, University of Hong Kong, and University of Oxford-AstraZeneca, Institut Pasteur-Themis-University of Pittsburgh, University of Queensland, Inovio Pharmaceuticals

Broadly Protective Coronavirus

SK bioscience, Intravacc, Codiak Biosciences, CPI-Caltech-University of Oxford-Ingenza, Bharat Biotech-University of Sydney-ExcellGene, MigVax Ltd, University of Saskatchewan's VIDO, THSTI & Panacea Biotech, BioNet, DIOSynVax, NEC Corporation, VBI Vaccines

Disease X

Tiba Biotech, SK bioscience, University of Queensland, Imperial College London, CureVac, IDD Leipzig, Houston Methodist Research Institute (HMRI)

For further information on CEPI please see CEPI’s website www.cepi.net.